Molecular Partners AG (MOLN) Stock Score, Valuation & Financial Research

Molecular Partners AG is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MOLN

Molecular Partners AG does not currently have a complete Wall Street Score. The stored market price is USD 4.10. These figures are a research snapshot, not a buy or sell recommendation.

What Molecular Partners AG does

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Molecular Partners is a clinical-stage biotechnology company that generates revenue primarily through research and development collaboration agreements with pharmaceutical partners. The company licenses its proprietary DARPin technology platform to these partners for the development of novel protein therapeutics, receiving upfront payments, research funding, and potential milestone or royalty payments upon the achievement of specific clinical or regulatory goals.

Products and services

  • The company develops DARPin therapeutics, a novel class of custom-built protein drugs designed to address medical challenges that other treatment modalities cannot readily address, focusing on oncology areas such as targeted radiopharmaceuticals and immune cell engagers.

Brands and product families

  • DARPin — Proprietary protein drug platform technology. Source

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, laboratory services, and the manufacturing of clinical trial materials. Specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Novartis — A collaboration agreement for the development of radioligand therapies using the company's DARPin technology. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with various entities developing protein-based therapeutics, immune cell engagers, and radiopharmaceuticals for oncology indications. Source

Business strengths to evaluate

  • Proprietary DARPin technology platform Source
  • Strong cash position and financial runway Source

Business risks and research considerations

  • Dependence on R&D partners for revenue and clinical success Source
  • Significant operating losses and history of no revenue Source
  • Risks associated with clinical trial outcomes and regulatory approval Source

Sources: Company research source · Novartis

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MOLN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.10
Market capitalization:
153.8M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -69.16M
Free cash flow:
USD -62.76M
Cash:
USD 81.74M
Total debt:
USD 3.66M
EPS:
USD -1.63

What stands out

  • Free cash flow is USD -62.76M, negative for the stored period.
  • The balance sheet shows USD 81.74M of cash versus USD 3.66M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 78.08M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MOLN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MOLN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MOLN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MOLN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MOLN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MOLN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.